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Endothelial cell chimerism occurs more often and earlier in
female than in male recipients of kidney transplants.
Background. Endothelial chimerism occurs in renal trans-
plants, but factors involved in its development and its impact
on outcome, are unknown. Most studies on chimerism are re-
stricted to gender-mismatched combinations of female donor
organs into male recipients. By using blood group antigen
mismatches to detect chimeric cells, we circumvented this re-
striction. We determined which factors predispose for the de-
velopment of endothelial chimerism, and how it influences graft
survival.
Methods. We studied 85 renal transplant biopsies of 24 pa-
tients with either blood group A or B, who received a blood
group O kidney. Biopsies were scored according to BANFF ’97.
Blood group antigens were stained by immunohistochemistry.
Semiquantitative scoring was performed by four independent
observers.
Results. Endothelial chimerism was found in 27/85 biopsies
from 16/24 patients. All female recipients, but only half of the
male recipients, had endothelial chimerism in their grafts (P <
0.025). In female recipients, endothelial chimerism occurred sig-
nificantly earlier than in male recipients (P < 0.02). The pres-
ence of endothelial chimerism was not associated with: rejec-
tion, outcome, original renal disease, previous transplantations,
age, warm/cold ischemia time, pretransplantation blood urea
levels, or erythropoietin therapy.
Conclusion. We are the first to report that endothelial
chimerism occurs significantly more often in female than in male
recipients of renal transplants. Endothelial chimerism had no
influence on graft outcome. We hypothesize that hormonal fac-
tors may influence the development of endothelial chimerism, in
parallel with differences in endothelial function between males
and females in cardiovascular disease.
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Endothelial chimerism in transplanted organs can be
defined as the presence of recipient derived endothe-
lial cells in the donor organ. Already in the early 1960s,
Medawar [1] hypothesized on the replacement of donor
by recipient endothelium in the kidney. He suggested that
in time, the endothelium of the donor organ would be-
come “owned” by the recipient, which would lead to graft
adaptation, a condition first described by Woodruff in
1950 [2]. Medawar believed that graft adaptation could
be induced by focal replacement of graft endothelial cells
by recipient cells, reducing the foreign antigen load. The
most likely reason for endothelial replacement in a trans-
planted organ would be loss of the original endothelial
lining due to, for instance, acute rejection, ischemia, or cy-
closporine toxicity. Endothelial progenitor cells replace
the damaged endothelium in the kidney after injury, a
phenomenon that has been elegantly described in ani-
mal models [3]. However, in time, a considerable num-
ber of endothelial cells may also be replaced as a result
of natural cell turnover [4], also referred to as endothe-
lial cell maintenance. Although endothelial cells of large
vessels in the kidney have a relatively low turnover rate
compared to, for instance, tubular epithelial cells [5], this
would nevertheless mean that even in the absence of in-
jury, in time, the endothelium of the transplanted kidney
would gradually be replaced by endothelial cells of recip-
ient origin. The question whether this would be benefi-
cial for graft survival, is still unanswered. It seems likely
that total endothelial replacement would indeed induce
graft tolerance. However, before this stage is reached,
endothelial cells of donor and of recipient origin would
have to be able to coexist in each other’s vicinity. It
is not inconceivable that this could lead to an immune
response.
We previously reported on the occurrence of endothe-
lial chimerism after renal transplantation [6], demon-
strating recipient-derived endothelial cells in the donor
kidney by blood group and human leukocyte antigen
(HLA) staining, and by in situ hybridization for X
and Y chromosomes, on the basis of donor-recipient
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mismatches. Endothelial chimerism was present in all
biopsies with interstitial and/or vascular rejection (N =
13), whereas it was absent in nine out of 13 biopsies with-
out rejection. The present study is an in depth investi-
gation into circumstances favoring the development of
endothelial chimerism, the time it requires to develop,
and its clinical consequences to the graft. We studied
a group of 24 renal transplantation patients with blood
groups A, B, or AB, who received blood group O kidneys.
By choosing blood group antigens as a read-out system
for endothelial chimerism, we were able to investigate
both gender-matched and gender-mismatched combina-
tions of donors and recipients.
We found endothelial chimerism to be present in all
female recipients (8/8), whereas it was present in only
half of the male recipients (8/16). Moreover, we found
that endothelial chimerism occurred much earlier after
transplantation in female than in male recipients. We are
the first to report a preference of endothelial chimerism
occurring in female graft recipients.
METHODS
Patients
Twenty-four patients with renal transplants were en-
tered into the study selected on the basis of a blood
group O donor kidney. There were nine blood group A
recipients, 14 blood group B recipients, and one blood
group AB recipient. Mean age at transplantation was
43 years (age range 29 to 62 years). Almost all pa-
tients were on dialysis before transplantation. Eight
patients, who had diabetes, received a combined kid-
ney/pancreas transplant. Seven of these patients became
insulin-independent after transplantation. Six patients
had had a previous renal transplantation. Several renal
biopsies were available from each patient, varying from
two to six biopsy specimens in a period of up to 13 years
after transplantation. Most biopsies were taken on clini-
cal grounds, except for a few biopsies of patients that were
entered into a study for which protocolized biopsies were
taken at several time points after transplantation. Six pre-
transplant biopsies were available, and included into the
study. Clinical characteristics of the patients are listed in
Table 1.
Biopsies
All biopsies were retrieved from the archives of the
Department of Pathology at Leiden University Medi-
cal Center, Leiden, The Netherlands. All tissue speci-
mens were reevaluated on the basis of a hematoxylin
an eosin, periodic acid-Schiff (PAS), and silver staining,
and histopathologically categorized into the follow-
ing groups: interstitial rejection (Banff ‘97 classifica-
tion IA/IB), vascular rejection (Banff ‘97 classification
IIA/IIB), chronic transplant nephropathy, acute tubular
necrosis, cyclosporine toxicity, recurrence of original dis-
ease, and other (mostly minor acute ischemic changes
without rejection). A small number of biopsies did not
show histopathologic lesions, and were categorized as “no
abnormalities.” All biopsies were scored according to the
complete Banff ’97 scoring system [7].
Renal function and outcome
Renal function at the time of biopsy [glomerular fil-
tration rate (GFR)] was determined by the Cockroft for-
mula, and categorized into three groups: normal (GFR
>60), moderately decreased (GFR between 30 and 59),
and severely decreased (GFR lower than 30). Graft out-
come was categorized as stable function, decline in func-
tion, or biopsy proven chronic allograft nephropathy. Of
one patient, outcome was not included into the analysis
because the graft was lost due to a posttransplant lym-
phoreticular disease within the first year after transplan-
tation.
Immunohistochemistry
Kidney sections from paraffin blocks were cut at 4 lm,
mounted on precoated slides, and kept at 37◦C
overnight. The slides were dewaxed in xylol for 20
minutes. Endogenous peroxidase activity was blocked
by methanol/hydrogen peroxidase. The primary anti-
bodies were monoclonal mouse IgM antiblood group
antigen A (clone 81FR2.2) and antiblood group anti-
gen B (clone3E7) antibodies (both were obtained from
Dako, Glostrup, Denmark). The primary antibodies
were applied to all slides and incubated overnight in
phosphate-buffered saline (PBS)/1% bovine serum albu-
min (BSA). A secondary rabbit-antimouse-horseradish
peroxidase–labeled antibody was used, followed by a ter-
tiary swine-antirabbit-horseradish peroxidase–labeled
antibody. Because both antibodies were monoclonal IgM
mouse antibodies, we could use them as alternate con-
trols. In blood group A patients, stainings with the an-
tiblood group B antibody were negative, whereas in blood
group B patients, stainings with the antiblood group A
antibody were negative.
All sections were scored twice, each time by two ob-
servers (four observers in total). Discrepant results were
discussed and solved during plenary sessions.
RESULTS
Endothelial chimerism was found in 28 out of 85 biop-
sies from 24 patients. Of all patients, 16 were found to
have endothelial chimerism at some point in time after
transplantation. Among these 16 patients with endothe-
lial chimerism, there was a remarkable distribution of
males and females. All female recipients in this study
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Male/Female Biopsies within first two months
of transplantation
Biopsies after 2 months, but within Biopsies after first year of transplantation
the first year of transplantation
F VR VR     IR
F ATN IR REC
F IR CTN CTN
F ATN IR IR CY IR CY CTN
F IR     IR CTN
F No early biopsy IR IR VR VR
F IR IR
F IR VR IR CTN
M NA CY CTN
M IR VR   VR
M CY IR OTHER
OTHER
IR OTHER
M NA IR CTN
M No early biopsy OTHER NA NA NA CTN
M NA NA IR NA IR CY VR
M IR IR     IR VR
M IR NA NA
M IR VR      VR
M IR VR REC REC
M IR IR
M ATN ATN   VR
VR
M VR CY
M ATN IR
M IR VR   IR VR
M IR IR CTN CY
: Chimerism present
NA : No abnormalities
CY : Cyclosporine toxicity
IR : Interstitial rejection
VR : Vascular rejection
CTN : Chronic transplant nephropathy
REC : Recurrent disease
Fig. 1. Renal biopsies during transplantation. Time course, diagnosis, and presence of endothelial chimerism.
(N = 8) developed chimerism in their renal grafts at some
point in time, whereas this was the case in only 50% of the
male recipients (eight out of 16). This difference is statisti-
cally significant (Fisher exact probability test, P < 0.025).
Moreover, female recipients were significantly earlier in
developing endothelial chimerism in their grafts. We di-
vided the time points at which the biopsies were taken
into very early (within the first 2 months of transplanta-
tion), early (after 2 months, but within the first year of
transplantation), and late (after the first year of trans-
plantation). Seven of eight female recipients and 15 of
16 male recipients had one or more very early biopsies.
Five of seven female recipients already had endothelial
chimerism in their very early biopsies, whereas this was
only the case in two out of 15 males (Fig. 1). This differ-
ence is statistically significant (Fisher exact probability
test, P < 0.02). The number of days after transplanta-
tion in which endothelial chimerism occurred for the first
time in female recipients was: 6, 6, 8, 22, and 57 days
after transplantation. In three biopsies, an interstitial re-
jection was present, in one a vascular rejection, and in
one acute tubular necrosis. The very early male recipient
biopsies with endothelial chimerism were taken 9 and 32
days after transplantation; both contained an interstitial
rejection.
The pattern of endothelial chimerism was essentially
the same in male and female recipients. Its appearance
was focal in all biopsies. If present, the chimeric ves-
sels always accounted for less than one third of the total
number of vessels in the biopsy. Endothelial chimerism
was mainly found in peritubular capillaries (Fig. 2A), but
also in glomerular capillaries (Fig. 2B), and in small and
large veins and arteries, sometimes in combination with
vascular rejection (Fig. 2C). Control sections (antiblood
group A in case of a blood group B–positive recipient and
vice versa) were always negative. Also the six pretrans-
plant biopsies were negative. Erythrocytes and leucocytes
in all transplant biopsies stained positive for antiblood
group A and antiblood group B in their respective posi-
tive recipients, serving as an internal positive control for
the staining of antiblood group A and antiblood group
B antibodies.
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A
B
C
Fig. 2. Endothelial chimerism. (A) Blood group O donor kidney in
blood group A recipient. Peritubular capillaries stain for blood group
A (arrows, magnification × 400). (B) Glomerular capillary. Blood group
O donor kidney in blood group A recipient. Arrow points to chimeric
endothelial cell. Staining for blood group A (magnification × 400). (C)
Vascular rejection. Large arrows point towards chimeric endothelial
cells expressing blood group A antigen. Small arrow points towards
area of endothelitis (magnification × 200).
Blood group phenotype and previous kidney trans-
plantation did not correlate with the presence of
chimerism at any point in time (Fisher exact probability
test, both P > 0.05), or with outcome (Fisher exact prob-
ability test, both P > 0.05). Before renal transplantation,
most patients were on dialysis (Table 1); their blood urea
levels did not predict for the occurrence of endothelial
chimerism (Student t test, P = 0.09). The original renal
diseases from which the patients suffered were various
(Table 1), but no distinct pattern could be found in rela-
tion to the occurrence of endothelial chimerism. Also, the
presence of endothelial chimerism at any point in time af-
ter transplantation was not associated with: blood group
phenotype, original renal disease, previous transplanta-
tions, donor or recipient age, or warm or cold ischemia
time (data not shown).
Vascular rejection within the first year of transplanta-
tion correlated significantly with an adverse outcome, in
comparison to interstitial rejection (Fisher exact proba-
bility test, P < 0.025). However, endothelial chimerism
did not correlate with graft function at the time of biopsy,
or with graft outcome. We analyzed whether the occur-
rence of endothelial chimerism at any time after trans-
plantation, in the first year of transplantation, or in the
first biopsy with acute rejection, correlated with graft
function at the time of follow-up biopsies or with long-
term outcome, but no statistically significant correlates
were found (data not shown).
A multivariate correlation analysis was performed to
analyze the scores from the Banff ’97 classification with
the presence of endothelial chimerism in each biopsy
specimen. The presence of endothelial chimerism corre-
lated positively with the presence of tubular atrophy (P <
0.03). All other histomorphologic parameters did not
correlate significantly with the presence of endothelial
chimerism.
DISCUSSION
We present the results of a study investigating cir-
cumstances favoring the development of endothelial
chimerism in renal allografts, the time it requires to de-
velop, and its clinical consequences to the graft. Our most
important findings are that endothelial chimerism shows
a preference of occurrence in renal grafts of female recip-
ients in comparison to those of male recipients, and that
endothelial chimerism occurs significantly earlier in renal
grafts of female than of male recipients. At the time of
biopsy, the presence of endothelial chimerism correlates
moderately with the presence of tubular atrophy, but the
presence of endothelial chimerism has no relation to a
vast number of clinical parameters, including graft func-
tion and outcome. This is in line with the results from a
recent study in epithelial chimerism in tubular epithelial
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cells of renal transplants [8], because also in this study,
chimerism did not correlate with allograft function [8].
That endothelial chimerism in a transplanted organ oc-
curs more often and earlier in female than in male re-
cipients has not been reported before. There have only
been few reports studying endothelial chimerism in trans-
planted kidneys, and the data are too few to draw conclu-
sions from the literature on the prevalence of chimerism
in female versus male recipients [9–12]. Moreover, be-
cause in situ hybridization of the Y chromosome is the
preferred method of detecting tissue chimerism in kid-
ney transplant studies as well as in transplantation stud-
ies on other organs [13–15], data on female recipients of
male donor organs are rare. Because in the present study
we studied tissue chimerism by looking at blood group
antigens, we were able to study all gender-matched and
gender-mismatched combinations of donors and recipi-
ents.
Why would female recipients of donor kidneys have
more endothelial cell chimerism in their grafts than male
recipients? The number of interstitial and vascular re-
jections was similar in both male and female recipients
in this study, there was no difference in warm or cold is-
chemia time, and cyclosporine toxicity was found in three
male and one female recipients. This means that dam-
age to the endothelium, as a prerequisite for endothe-
lial replacement to take place, may be considered equal
in the male and the female recipients of this study. Is
it possible then, that our finding accidentally reflects a
physiologic difference in endothelial maintenance or in
endothelial cell repair between men and women? There
are data on differences in vessel physiology of men and
women, mostly initiated by the fact that premenopausal
women have a significantly lower risk of cardiovascular
disease than men. Six of the women in our study were pre-
menopausal, whereas two were postmenopausal. There
was no difference between the early and late occurrence
of endothelial chimerism between the pre- and the post-
menopausal women (two women did not have endothe-
lial chimerism in their early biopsies, and these two were
premenopausal). However, these subgroups are too small
to draw firm conclusions.
The finding that premenopausal women have a sig-
nificantly lower risk of cardiovascular disease is largely
contributed to the protective actions of estrogen and pro-
gesterone [16]. These hormones have been shown to re-
duce low-density lipoprotein (LDL) cholesterol levels, to
increase high-density lipoprotein (HDL) cholesterol lev-
els [16], and to induce vascular relaxation through their
effects on nitric oxide cyclic guanosine monophosphate
(cGMP) [17]. Thus, they contribute to a reduction of car-
diovascular risk factors, such as high cholesterol levels
and hypertension, in women. Whether the female sex hor-
mones also have an effect on endothelial cell turnover
has, to our knowledge, not been studied systematically.
It is known, however, that these hormones stimulate an-
giogenesis, and this occurs mostly via stimulation of vas-
cular endothelial growth factor (VEGF) [18]. VEGF is
a potent angiogenic factor that is up regulated after en-
dothelial damage, for instance due to ischemia, to attract
progenitor endothelial cells from the bone marrow to the
damaged vessel [19]. VEGF is stimulated by estrogens,
a process mediated by enhanced endothelial nitric oxide
production. It has been reported that in healthy blood
donors, VEGF levels are higher in women than in men
[20], though others have reported that they are the same
[21]. Unfortunately, we were unable in this historic pa-
tient group to determine the VEGF levels of the recipi-
ents at the time of transplantation.
It is tempting to hypothesize that in women endothe-
lial cell turnover would be faster than in men under the
influence of estrogens that stimulate VEGF, a potent
angiogenic factor. Therefore, in the event of endothe-
lial damage in a transplanted kidney, female recipients
could have a benefit over male recipients in repairing this
damage because they have a stronger, estrogen-mediated
VEGF response. Differences in VEGF levels between
male and female recipients of renal grafts have, to our
knowledge, not been studied so far. However, that high
VEGF levels can be beneficial to renal graft function was
reported in a recent study by Lemos et al [22], show-
ing a positive correlation between VEGF levels and re-
nal graft function in relation to ischemia/reperfusion in-
jury. Outside the renal transplantation field, VEGF was
shown to enhance glomerular capillary repair [23, 24],
whereas in slowly progressive disease, for in stance in
diabetic nephropathy, VEGF expression was reduced
[25].
Other factors which could have influenced the differ-
ence in development of endothelial chimerism between
female and male recipients could have been erythropoi-
etin therapy and blood urea levels before transplanta-
tion. There is evidence that erythropoietin enhances the
proliferation and differentiation of endothelial precur-
sor cells in renal patients [26]. Therefore, more endothe-
lial chimerism would be expected in patients who had
erythropoietin therapy. However, in this historic group,
only four patients, two males and two females, received
erythropoietin therapy. The two male recipients who re-
ceived erythropoietin did not have endothelial chimerism
in any of their renal transplant biopsies. The female re-
cipients who received erythropoietin did, but so did all
the other female recipients in our study. We also looked
for a relation between the occurrence of endothelial
chimerism and blood urea levels before transplantation.
Uremia may inhibit proliferation of endothelial precur-
sor cells, and therefore, higher blood urea levels could
possibly lead to less endothelial chimerism [27]. By com-
paring the data with the Student t test, we could not
demonstrate a relationship between blood urea levels
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and the occurrence of endothelial chimerism. However,
given that our group is relatively small, it is telling that
the two female recipients who did not have early endothe-
lial chimerism were the ones with the highest blood urea
levels in the female population.
Could the preference of occurrence of endothelial
chimerism in female over male recipients have signifi-
cance for clinical outcome? Our study does not seem to
indicate this, as the outcome in our study group is simi-
lar in male and female recipients. However, the relatively
small size of our patient group could have influenced this
finding. Long-term outcome of donor kidney recipients
has been described in larger group studies to be better
in female than in male recipients, both in humans [28]
and in animal models [29, 30], attributed to differences
in sex hormones. What do these results mean in terms
of therapeutic options? Successful endothelial repair by
the administration of VEGF in a rat model of heart trans-
plantation has already been reported. Perhaps in the near
future, exogenous VEGF administration could play a role
in the prevention of renal graft loss. For the moment, how-
ever, the relationship between VEGF levels, endothelial
chimerism, sex hormones, and graft survival still awaits
further clarification.
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